Treatment of Type 1 Diabetes With Anti-OX40L Bispecific With Anti-TNF Activity In a Single Nanobody® Molecule

Clinical trial NCT06812988 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT06812988
Sponsor: Sanofi
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Type 1 Diabetes Mellitus

Start date: 2025-02-28
Primary completion: 2027-04-29
Enrollment: 84

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.